NZ631144A - Compositions and methods for transmucosal absorption - Google Patents

Compositions and methods for transmucosal absorption

Info

Publication number
NZ631144A
NZ631144A NZ631144A NZ63114413A NZ631144A NZ 631144 A NZ631144 A NZ 631144A NZ 631144 A NZ631144 A NZ 631144A NZ 63114413 A NZ63114413 A NZ 63114413A NZ 631144 A NZ631144 A NZ 631144A
Authority
NZ
New Zealand
Prior art keywords
methods
compositions
transmucosal absorption
agent
amitryptyline
Prior art date
Application number
NZ631144A
Other languages
English (en)
Inventor
Seth Lederman
Giorgio Reiner
Harry Brittain
Original Assignee
Tonix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tonix Pharmaceuticals Inc filed Critical Tonix Pharmaceuticals Inc
Priority to NZ726488A priority Critical patent/NZ726488A/en
Publication of NZ631144A publication Critical patent/NZ631144A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
NZ631144A 2012-06-15 2013-06-14 Compositions and methods for transmucosal absorption NZ631144A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ726488A NZ726488A (en) 2012-06-15 2013-06-14 Compositions and methods for transmucosal absorption

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261660593P 2012-06-15 2012-06-15
US201261667774P 2012-07-03 2012-07-03
US201261725402P 2012-11-12 2012-11-12
US201361792900P 2013-03-15 2013-03-15
PCT/US2013/046023 WO2013188847A1 (en) 2012-06-15 2013-06-14 Compositions and methods for transmucosal absorption

Publications (1)

Publication Number Publication Date
NZ631144A true NZ631144A (en) 2016-12-23

Family

ID=49758769

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ726488A NZ726488A (en) 2012-06-15 2013-06-14 Compositions and methods for transmucosal absorption
NZ631144A NZ631144A (en) 2012-06-15 2013-06-14 Compositions and methods for transmucosal absorption

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ726488A NZ726488A (en) 2012-06-15 2013-06-14 Compositions and methods for transmucosal absorption

Country Status (26)

Country Link
US (1) US20140171515A1 (enExample)
EP (1) EP2861223B1 (enExample)
JP (5) JP6259452B2 (enExample)
CN (2) CN104684550A (enExample)
AR (1) AR092330A1 (enExample)
AU (2) AU2013274003B2 (enExample)
BR (1) BR112014031394B1 (enExample)
CA (2) CA3118913C (enExample)
DK (1) DK2861223T3 (enExample)
ES (1) ES2929133T3 (enExample)
HR (1) HRP20221325T1 (enExample)
HU (1) HUE060175T2 (enExample)
IL (1) IL236268B (enExample)
LT (1) LT2861223T (enExample)
MX (2) MX382516B (enExample)
MY (1) MY194495A (enExample)
NZ (2) NZ726488A (enExample)
PL (1) PL2861223T3 (enExample)
PT (1) PT2861223T (enExample)
RS (1) RS63822B1 (enExample)
SG (2) SG11201408318RA (enExample)
SI (1) SI2861223T1 (enExample)
SM (1) SMT202200436T1 (enExample)
TW (3) TWI683660B (enExample)
WO (1) WO2013188847A1 (enExample)
ZA (1) ZA201500288B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20171739T1 (hr) 2009-11-20 2018-03-09 Tonix Pharma Holdings Limited Postupci i kompozicije za liječenje simptoma povezanih s posttraumatskim stresnim poremećajem korištenjem ciklobenzaprina
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
HUE047547T2 (hu) 2013-03-15 2020-04-28 Tonix Pharma Holdings Ltd Ciklobenzaprin-hidroklorid és mannit eutektikus formulációi
SG10201902203VA (en) * 2014-09-18 2019-04-29 Tonix Pharma Holdings Ltd Eutectic formulations of cyclobenzaprine hydrochloride
WO2017009472A1 (en) * 2015-07-15 2017-01-19 Theranexus Use of amitriptyline for blocking brain hemichannels and method for potentiating its effect in vivo
WO2018045367A1 (en) * 2016-09-02 2018-03-08 Nova Southeastern University Atropine sulfate rapidly-disintegrating sublingual tablets for treatment of acute organophosphate toxicity
JP2020526592A (ja) * 2017-07-13 2020-08-31 トニックス ファーマシューティカルズ ホールディング コーポレーション シクロベンザプリン類似体及びアミトリプチレン類似体
CN107496355B (zh) * 2017-08-24 2021-04-30 正大制药（青岛）有限公司 一种盐酸环苯扎林舌下喷雾剂及其制备方法
CN107519142B (zh) * 2017-08-24 2021-02-26 正大制药（青岛）有限公司 一种盐酸环苯扎林舌下片及其制备方法
IL275144B2 (en) * 2017-12-08 2024-12-01 Hoffmann La Roche Pharmaceutical formulation
WO2019116091A1 (en) 2017-12-11 2019-06-20 Tonix Pharma Holdings Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
CN108721240A (zh) * 2018-06-08 2018-11-02 华益药业科技(安徽)有限公司 一种25mg阿米替林薄膜包衣片处方和工艺规程
SG11202101443WA (en) * 2018-08-20 2021-03-30 Tonix Pharma Holdings Ltd Methods of treating acute stress disorder and posttraumatic stress disorder
CA3156118A1 (en) * 2019-09-30 2021-04-08 Cadila Healthcare Limited Intranasal pharmaceutical compositions of cyclobenzaprine
CA3179754A1 (en) * 2020-04-08 2021-10-14 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for sexual dysfunction
WO2022109218A1 (en) * 2020-11-20 2022-05-27 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for alcohol use disorder
WO2022125572A1 (en) 2020-12-07 2022-06-16 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for fibromyalgia
WO2022170107A2 (en) 2021-02-04 2022-08-11 Tonix Pharmaceuticals Holding Corp. An improved method of assessing clinical response in the treatment of ptsd symptoms
WO2023059728A1 (en) 2021-10-06 2023-04-13 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine for treatment or prevention of sexual dysfunction associated with mental health conditions in female patients
US20230414536A1 (en) 2022-06-21 2023-12-28 Tonix Pharmaceuticals Holding Corp. CYCLOBENZAPRINE TREATMENT FOR POST-ACUTE SEQUELAE OF (SARS)-CoV-2 INFECTION (PASC)
WO2025160302A1 (en) 2024-01-25 2025-07-31 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for acute stress reaction or acute stress disorder

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
WO1999018937A1 (en) * 1997-10-16 1999-04-22 Merck & Co., Inc. New cyclobenzaprine composition
EP1077683B1 (en) * 1998-05-14 2002-12-11 Alza Corporation Antidepressant therapy
HK1047693A1 (zh) 1999-08-13 2003-03-07 Vela Pharmaceuticals Inc. 治疗全身性焦虑障碍的环苯扎林及其组合物
PT1202722E (pt) 1999-08-13 2005-11-30 L & L Technologies Llc Usos para o tratamento ou prevencao de disturbios do sono usando doses muito baixas de ciclobenzaprina
AU2001261744A1 (en) * 2000-05-19 2001-12-03 Npd Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
WO2002094229A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of muscle relaxants through an inhalation route
JP2006516963A (ja) * 2003-02-04 2006-07-13 クリサリス テクノロジーズ インコーポレイテッド エアロゾル製剤及びブスピロン、ブプレノルフィン、トリアゾラム、シクロベンザプリン及びゾルピデムのエアロゾル送出
US20090117054A1 (en) * 2005-03-29 2009-05-07 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
US20090148532A1 (en) * 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms
JP2009079060A (ja) * 2008-10-15 2009-04-16 Novadel Pharma Inc 極性または非極性の、バッカルスプレーまたはカプセル
US20100266682A1 (en) * 2008-12-10 2010-10-21 Nipun Davar Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same
US20100247586A1 (en) * 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
HRP20171739T1 (hr) * 2009-11-20 2018-03-09 Tonix Pharma Holdings Limited Postupci i kompozicije za liječenje simptoma povezanih s posttraumatskim stresnim poremećajem korištenjem ciklobenzaprina
US20110319389A1 (en) * 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
ITMI20110558A1 (it) * 2011-04-06 2012-10-07 Campiglio Consulting Srl Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale
HUE047547T2 (hu) * 2013-03-15 2020-04-28 Tonix Pharma Holdings Ltd Ciklobenzaprin-hidroklorid és mannit eutektikus formulációi

Also Published As

Publication number Publication date
SG11201408318RA (en) 2015-01-29
AR092330A1 (es) 2015-04-15
HK1209361A1 (en) 2016-04-01
MX2021005317A (es) 2022-12-16
PL2861223T3 (pl) 2022-12-12
HRP20221325T1 (hr) 2022-12-23
TWI590820B (zh) 2017-07-11
EP2861223A4 (en) 2016-01-27
RS63822B1 (sr) 2023-01-31
DK2861223T3 (da) 2022-11-07
TW201731494A (zh) 2017-09-16
TW201408281A (zh) 2014-03-01
CA2876902A1 (en) 2013-12-19
SG10201605407TA (en) 2016-08-30
CN111388430A (zh) 2020-07-10
JP6259452B2 (ja) 2018-01-10
TWI642429B (zh) 2018-12-01
CN104684550A (zh) 2015-06-03
BR112014031394A8 (pt) 2021-11-03
US20140171515A1 (en) 2014-06-19
JP2019123757A (ja) 2019-07-25
ZA201500288B (en) 2022-05-25
WO2013188847A1 (en) 2013-12-19
AU2013274003A1 (en) 2015-02-05
MY194495A (en) 2022-11-30
EP2861223A1 (en) 2015-04-22
IL236268B (en) 2022-03-01
WO2013188847A8 (en) 2015-02-05
JP2015519404A (ja) 2015-07-09
IL236268A0 (en) 2015-02-26
JP2021138765A (ja) 2021-09-16
AU2018241128A1 (en) 2018-10-25
SI2861223T1 (sl) 2023-01-31
MX382516B (es) 2025-03-13
NZ726488A (en) 2018-10-26
AU2013274003B2 (en) 2018-07-05
BR112014031394B1 (pt) 2022-10-18
AU2018241128B2 (en) 2020-05-21
SMT202200436T1 (it) 2023-01-13
JP2024032964A (ja) 2024-03-12
EP2861223B1 (en) 2022-08-03
TWI683660B (zh) 2020-02-01
CA3118913A1 (en) 2013-12-19
CA2876902C (en) 2021-07-13
TW201842903A (zh) 2018-12-16
ES2929133T3 (es) 2022-11-25
JP2017222726A (ja) 2017-12-21
BR112014031394A2 (pt) 2017-06-27
LT2861223T (lt) 2022-12-12
CA3118913C (en) 2024-04-30
MX2014015436A (es) 2015-07-14
PT2861223T (pt) 2022-11-07
HUE060175T2 (hu) 2023-02-28

Similar Documents

Publication Publication Date Title
NZ631144A (en) Compositions and methods for transmucosal absorption
IN2014DN09434A (enExample)
GB201118656D0 (en) New compounds
MY188139A (en) Sodium channel modulators for the treatment of pain
PH12014501561A1 (en) Therapeutically active compounds and their methods of use
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
MX366899B (es) Nuevos compuestos.
AU2011328009A8 (en) Compounds and methods for treating pain
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
IN2012DN06720A (enExample)
MX349004B (es) Nuevos compuestos.
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
PH12013500955A1 (en) Spiro-oxindole mdm2 antagonists
PH12013502261A1 (en) Partially saturated tricyclic compounds and methods of making and using same
PH12014500386A1 (en) Combination treatment for hepatitis c
IN2015DN03219A (enExample)
MX2014008705A (es) Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
MX2015004362A (es) Derivados de ketamina.
MX2015005732A (es) Compuestos tricíclicos y métodos para hacer y utilizar los mismos.
EP4302825A3 (en) Pharmaceutical compositions for treatment of inappetence
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
WO2013096335A8 (en) ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT
MD20160066A2 (ro) Modulatoare alosterice pozitive ale receptorului nicotinic acetilcolinic
NZ707636A (en) Ingenol-derived compounds that can be used for treating cancer

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE OWNER HAS BEEN CORRECTED TO 3156945, TONIX PHARMACEUTICALS, INC., 509 MADISON AVENUE, SUITE 306NEW YORK, NEW YORK 10022, US

Effective date: 20150129

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2018 BY CULLENS PTY LTD

Effective date: 20170614

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2019 BY COMPUTER PACKAGES INC

Effective date: 20180619

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2020 BY CPA GLOBAL

Effective date: 20190502

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2021 BY CPA GLOBAL

Effective date: 20200604

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2022 BY CPA GLOBAL

Effective date: 20210506

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2023 BY CPA GLOBAL

Effective date: 20220505

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2024 BY CPA GLOBAL

Effective date: 20230504

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240606

ASS Change of ownership

Owner name: TONIX PHARMA LIMITED, IE

Effective date: 20250325

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250515